Jeremy Teoh
@jteoh_hk
Assistant Dean @CUHKMedicine | AE @EurUrolOncol | EAU Guidelines Office | EAU-YAU UC Working Group | SIU Congress Chair | SIU Innovators | #UroSoMe!
The EB-StaR study was published at European Urology today! ✅ It is a randomised study comparing en bloc resection of bladder tumour (ERBT) and conventional transurethral resection of bladder tumour (TURBT) in patients with bladder tumour(s) <= 3 cm in size. 🏥 #UroSoMe (1/n)
10 years ago, under the vision of @NDowJames, we set out to bring #EAUGuidelines to #socialmedia . It started with a small group, driven by the belief that guidelines become truly valuable when they are shared, discussed, and used together. Leading that first Dissemination…
Big news! We have launched our first Scientific Advisory Board, a global group of urologists, oncologists, nurses & researchers guiding us with the latest science 💡 🧠 Led by @UroDocAsh, this marks a new era in patient-focused, evidence-based care. Meet the…
Congrats @MatteoSantoniMD It was our privilege to highlight this excellent article released in our journal a few months ago @EurUrolOncol @Ric_Campi @LauraMarandino @UroDocAsh @Ecastromarcos @GPloussard @CaPsurvivorship @RenuEapen @jteoh_hk @Uroweb
Kudos to my friend @MatteoSantoniMD who received the prize for the best paper published on @EurUrolOncol in 2024 at #UROonco25 in Seville. @urofocus @oncodaily @EUplatinum @Uroweb @fmassari79 @foxal72 @MRoupret
#UROonco25 starting today in the beautiful city of #Sevilla. Top experts from Europe and beyond come together to discuss about diagnosis and treatment of GU cancers. #ProstateCancer #KidneyCancer #BladderCancer Knowledge sharing and latest research with the common goal to…
💫 Exciting news! Yet another milestone as @EurUrolOncol continues to increase its Impact Factor year after year. Congratulations to the entire team, and especially @MRoupret for your innovative leadership. Honored to have been part of this since the inception @Uroweb…
Hats off to your stellar leadership and vision, Morgan. Honored to be part of the @EurUrolOncol journey since its inception!
So proud to be part of this wonderful team @EurUrolOncol !! Our goal is clear - Always aim for impact!!
So proud of my team !!! 😎@EurUrolOncol we have a rise of one point of our impact factor over the last year. Congrats for the great achievement @RenuEapen @Ric_Campi @CaPsurvivorship @Ecastromarcos @UroDocAsh @jteoh_hk @LauraMarandino @GPloussard we deliver for @Uroweb
Thank you @MRoupret for your inspiring leadership and constant support! I am honored and proud to be part of this amazing #team! 💪🏻@EurUrolOncol
🎉Our work was published at European Urology today! 🪭Randomized noninferiority trial: Flexible and Navigable Suction Ureteral Access Sheath flexible ureteroscopy #FANS #fURS vs #miniPCNL in 2-3cm renal stone 🔗 doi.org/10.1016/j.euru… #GuohuaZeng #WeiZhu #fansofFANS #UroSoMe
Wonderful news! #JCR2025 Big congratulations to the team. #TrustedJournals
So proud of my team !!! 😎@EurUrolOncol we have a rise of one point of our impact factor over the last year. Congrats for the great achievement @RenuEapen @Ric_Campi @CaPsurvivorship @Ecastromarcos @UroDocAsh @jteoh_hk @LauraMarandino @GPloussard we deliver for @Uroweb
Applaud the effort, a word of caution before people rush to use this in practice. Have seen young pts with NMIBC with +ctDNA misclassified as mUC and treated as such - despite no clinical or imaging evidence of mets. The emotional and social fallout for patients and families…
🧬 Practice-changing insights👇 ctDNA role in high risk NMIBC ( T1HG and BCG unresponsive). First pub @CleClinicUro as we continue to learn more -- ctDNA is detectable in 35% of highest-risk NMIBC 💥 ctDNA+ often flags recurrence or upstaging ~3mo before imaging. In BCG-naïve:…
A 🧵 on our recent study on surveillance for IR-NMIBC @EurUrolOncol authors.elsevier.com/c/1l7pU_wtP00L… There is limited evidence on follow-up for IR-NMIBC. We used data from >2000 primary Ta–T1 NMIBC to stratify IR-NMIBC by recurrence risk and propose a risk-adapted follow-up approach.
Delighted to have completed my certification from @harvardmed 🇺🇸 in “Artifical Intellegence in Health Care - From Stratergies and Implementation”. Enjoyed every minute of the programme. @enherts @UniofHerts @prokarurol @MrTimLane @KarelDecaestec1 @joeurol @jteoh_hk @rylance_amy
In a recent editorial, Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery), (@jteoh_hk) makes a case for the shift from conventional TURBT to transurethral en bloc resection of bladder tumor. @CUHKMedicine urologytimes.com/view/en-bloc-r…
Big step for the #EAUGuidelines: Today we introduced our own EAU Guidelines Chatbot — a smart assistant that delivers guideline-backed answers, instantly. Built by us. Powered by our content. Because no one explains the Guidelines better than those who write them. @Uroweb…
NEW: The EAU Guidelines Bot The right answers, seconds away Ask personalised treatment questions and receive instant answers based on the EAU Guidelines. Available in each topic section of the EAU Guidelines. Try it today via the Guidelines page: uroweb.org/guidelines
Yes, randomization should and can be done #NMIBC ✅ Get high quality #TURBT as first part of the comparator - critical missing piece right now ✅ +adjuvant treatment per risk categor and Standard of Care/Investigator‘s choice to keep trials feasible #ASCO25 @tompowles1 @oncodaily
Different novel therapies in NMIBC are approved #ASCO @AndreaNecchi @MattGalsky Most are being tested in BCG pretreated patients. All have activity & many have a favourite, but with small single arm trials no one knows which is best. Now there are choices we should randomise?